The first-in-human clinical trial evaluated the safety and biodistribution of two novel MC1R-targeted imaging tracers ([203Pb]VMT01 and [68Ga]VMT02) in stage IV melanoma patients to support the development of MC1R-targeted alpha-particle therapy. This evidence concerns the gene MC1R and melanoma.